XLO
Xilio Therapeutics, Inc.
Price Chart
Latest Quote
$9.03
-0.09 (-0.99%)
Current Price
| Previous Close | $9.12 |
| Open | $9.02 |
| Day High | $9.14 |
| Day Low | $8.96 |
| Volume | 115,867 |
Stock Information
| Shares Outstanding | 6.58M |
| Total Debt | $6.64M |
| Cash Equivalents | $150.33M |
| Revenue | $53.48M |
| Net Income | $-31.30M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $58.39M |
| EPS (TTM) | $-2.28 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-90.57M |
| Sales | $53.48M |
| Income | $-31.30M |
| Book/sh | $7.79 |
| Cash/sh | $22.86 |
| Employees | 76 |
Financial Ratios
| Quick Ratio | 3.50 |
| Current Ratio | 3.59 |
| Debt/Eq | 9.15 |
Returns & Margins
| ROA | -19.76% |
| ROE | -75.20% |
| Gross Margin | 79.13% |
| Operating Margin | -111.58% |
| Profit Margin | -58.52% |
Ownership
| Insider Ownership | 28.58% |
| Institutional Ownership | 51.84% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -15.31 |
| P/S | 1.09 |
| P/B | 1.14 |
Analyst Data
| Recommendation | none |
| Target Price | $20.00 |
Technical Indicators
| SMA20 | $9.12 |
| SMA50 | $8.55 |
| SMA200 | $9.06 |
| RSI | 46.26 |
| ATR | 0.4000 |
| Shares Float | 3.75M |
| Short Float | 2.97% |
| Short Ratio | 4.84 |
| Volatility | -0.12 |
| Rel Volume | 0.98 |
Performance History
| Week | -2.42% |
| Month | +7.64% |
| Quarter | +6.35% |
| 6 Months | -1.81% |
| YTD | -5.61% |
| Year | -13.11% |
| 3 Years | -76.68% |
| 10 Years | -96.04% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $8.88 | 55,700 |
| 2026-07-16 | $9.03 | 115,900 |
| 2026-07-15 | $9.12 | 75,100 |
| 2026-07-14 | $9.03 | 105,200 |
| 2026-07-13 | $9.24 | 71,500 |
| 2026-07-10 | $9.10 | 19,000 |
| 2026-07-09 | $9.20 | 19,900 |
| 2026-07-08 | $9.28 | 65,000 |
| 2026-07-07 | $9.31 | 193,700 |
| 2026-07-06 | $9.44 | 10,100 |
| 2026-07-02 | $9.15 | 16,400 |
| 2026-07-01 | $9.22 | 22,500 |
| 2026-06-30 | $9.58 | 26,200 |
| 2026-06-29 | $9.27 | 155,500 |
| 2026-06-26 | $9.05 | 43,900 |
| 2026-06-25 | $8.89 | 9,400 |
| 2026-06-24 | $9.01 | 17,800 |
| 2026-06-23 | $8.90 | 32,300 |
| 2026-06-22 | $8.94 | 26,100 |
| 2026-06-18 | $8.79 | 56,700 |
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
đ° Latest News
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-12T12:40:04Z
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-12T12:20:01Z
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-11T22:05:08Z
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?
Zacks âĸ 2026-04-01T16:00:06Z
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
Zacks âĸ 2026-03-26T13:18:00Z
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates
Zacks âĸ 2025-11-12T13:25:01Z
Xilio Therapeutics Second Quarter 2025 Earnings: US$0.16 loss per share (vs US$0.32 loss in 2Q 2024)
Simply Wall St. âĸ 2025-08-16T13:54:14Z
Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates
Zacks âĸ 2025-08-14T12:35:02Z
Snap downgraded, Leidos upgraded: Wall Street's top analyst calls
The Fly âĸ 2025-08-06T13:36:40Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $43,766,000 | $6,344,000 | $0 | $0 |
| Operating Revenue | $43,766,000 | $6,344,000 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $85,748,000 | $65,989,000 | $79,133,000 | $89,149,000 |
| Other Income Expense | $6,946,000 | $1,404,000 | $2,729,000 | $927,000 |
| Other Non Operating Income Expenses | $1,101,000 | $2,341,000 | $2,729,000 | $927,000 |
| Operating Expense | $85,748,000 | $65,989,000 | $79,133,000 | $89,149,000 |
| General And Administrative Expense | $29,709,000 | $24,778,000 | $26,997,000 | $29,948,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-35,036,000 | $-58,241,000 | $-76,404,000 | $-88,222,000 |
| Normalized Income | $-40,881,000 | $-57,304,000 | $-76,404,000 | $-88,222,000 |
| Net Income From Continuing And Discontinued Operation | $-35,036,000 | $-58,241,000 | $-76,404,000 | $-88,222,000 |
| Total Operating Income As Reported | $-41,982,000 | $-60,582,000 | $-79,133,000 | $-89,149,000 |
| Net Income Common Stockholders | $-35,036,000 | $-58,241,000 | $-76,404,000 | $-88,222,000 |
| Net Income | $-35,036,000 | $-58,241,000 | $-76,404,000 | $-88,222,000 |
| Net Income Including Noncontrolling Interests | $-35,036,000 | $-58,241,000 | $-76,404,000 | $-88,222,000 |
| Net Income Continuous Operations | $-35,036,000 | $-58,241,000 | $-76,404,000 | $-88,222,000 |
| Pretax Income | $-35,036,000 | $-58,241,000 | $-76,404,000 | $-88,222,000 |
| Special Income Charges | $0 | $-937,000 | $0 | - |
| Operating Income | $-41,982,000 | $-59,645,000 | $-79,133,000 | $-89,149,000 |
| Per Share | ||||
| Diluted EPS | $-4.19 | $-15.26 | $-38.92 | $-45.08 |
| Basic EPS | $-4.19 | $-15.26 | $-38.92 | $-45.08 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-46,286,000 | $-57,064,000 | $-77,233,000 | $-87,302,000 |
| Total Unusual Items | $5,845,000 | $-937,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $5,845,000 | $-937,000 | $0 | - |
| Reconciled Depreciation | $1,541,000 | $1,644,000 | $1,900,000 | $1,847,000 |
| EBITDA (Bullshit earnings) | $-40,441,000 | $-58,001,000 | $-77,233,000 | $-87,302,000 |
| EBIT | $-41,982,000 | $-59,645,000 | $-79,133,000 | $-89,149,000 |
| Diluted Average Shares | $8,359,108 | $3,822,244 | $1,964,007 | $1,956,577 |
| Basic Average Shares | $8,359,108 | $3,822,244 | $1,964,007 | $1,956,577 |
| Diluted NI Availto Com Stockholders | $-35,036,000 | $-58,241,000 | $-76,404,000 | $-88,222,000 |
| Restructuring And Mergern Acquisition | $0 | $937,000 | $0 | - |
| Gain On Sale Of Security | $5,845,000 | - | - | - |
| Research And Development | $56,039,000 | $41,211,000 | $52,136,000 | $59,201,000 |
| Selling General And Administration | $29,709,000 | $24,778,000 | $26,997,000 | $29,948,000 |
| Other Gand A | $13,388,000 | $10,132,000 | $11,170,000 | $13,247,000 |
| Salaries And Wages | $16,321,000 | $14,646,000 | $15,827,000 | $16,701,000 |
Fetched: 2026-07-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $35,273,000 | $17,598,000 | $36,827,000 | $105,647,000 |
| Total Assets | $154,685,000 | $71,075,000 | $60,926,000 | $139,165,000 |
| Total Non Current Assets | $9,658,000 | $10,841,000 | $12,799,000 | $14,669,000 |
| Other Non Current Assets | $1,807,000 | $1,782,000 | $1,732,000 | $1,829,000 |
| Current Assets | $145,027,000 | $60,234,000 | $48,127,000 | $124,496,000 |
| Other Current Assets | $2,496,000 | $4,943,000 | $3,423,000 | $4,111,000 |
| Receivables | $5,000,000 | $0 | - | - |
| Other Receivables | $5,000,000 | - | - | - |
| Cash Cash Equivalents And Short Term Investments | $137,531,000 | $55,291,000 | $44,704,000 | $120,385,000 |
| Cash And Cash Equivalents | $137,531,000 | $55,291,000 | $44,704,000 | $120,385,000 |
| Prepaid Assets | - | - | - | $4,111,000 |
| Debt | ||||
| Total Debt | $6,954,000 | $8,142,000 | $12,504,000 | $19,939,000 |
| Long Term Debt And Capital Lease Obligation | $5,611,000 | $6,954,000 | $8,142,000 | $12,354,000 |
| Current Debt And Capital Lease Obligation | $1,343,000 | $1,188,000 | $4,362,000 | $7,585,000 |
| Current Debt | - | - | $3,315,000 | $6,667,000 |
| Other Current Borrowings | - | - | $3,315,000 | $6,667,000 |
| Long Term Debt | - | - | - | $3,165,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $119,412,000 | $53,477,000 | $24,099,000 | $33,518,000 |
| Total Non Current Liabilities Net Minority Interest | $63,139,000 | $26,216,000 | $8,142,000 | $12,399,000 |
| Other Non Current Liabilities | $7,333,000 | - | - | $45,000 |
| Derivative Product Liabilities | $29,560,000 | $0 | - | - |
| Non Current Deferred Liabilities | $20,635,000 | $19,262,000 | $0 | - |
| Current Liabilities | $56,273,000 | $27,261,000 | $15,957,000 | $21,119,000 |
| Current Deferred Liabilities | $40,023,000 | $13,518,000 | $0 | - |
| Payables And Accrued Expenses | $9,174,000 | $8,347,000 | $6,857,000 | $8,039,000 |
| Payables | $3,168,000 | $2,574,000 | $1,050,000 | $3,125,000 |
| Accounts Payable | $3,168,000 | $2,574,000 | $1,050,000 | $3,125,000 |
| Other Current Liabilities | - | - | $48,000 | $82,000 |
| Equity | ||||
| Common Stock Equity | $35,273,000 | $17,598,000 | $36,827,000 | $105,647,000 |
| Total Equity Gross Minority Interest | $35,273,000 | $17,598,000 | $36,827,000 | $105,647,000 |
| Stockholders Equity | $35,273,000 | $17,598,000 | $36,827,000 | $105,647,000 |
| Retained Earnings | $-418,789,000 | $-383,753,000 | $-325,512,000 | $-249,108,000 |
| Other | ||||
| Ordinary Shares Number | $4,530,640 | $3,268,340 | $1,971,974 | $1,958,960 |
| Share Issued | $4,530,640 | $3,268,340 | $1,971,974 | $1,958,960 |
| Tangible Book Value | $35,273,000 | $17,598,000 | $36,827,000 | $105,647,000 |
| Invested Capital | $35,273,000 | $17,598,000 | $40,142,000 | $115,479,000 |
| Working Capital | $88,754,000 | $32,973,000 | $32,170,000 | $103,377,000 |
| Capital Lease Obligations | $6,954,000 | $8,142,000 | $9,189,000 | $10,107,000 |
| Total Capitalization | $35,273,000 | $17,598,000 | $36,827,000 | $108,812,000 |
| Additional Paid In Capital | $454,062,000 | $401,351,000 | $362,336,000 | $354,752,000 |
| Capital Stock | $0 | $0 | $3,000 | $3,000 |
| Common Stock | $0 | $0 | $3,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $20,635,000 | $19,262,000 | $0 | - |
| Long Term Capital Lease Obligation | $5,611,000 | $6,954,000 | $8,142,000 | $9,189,000 |
| Current Deferred Revenue | $40,023,000 | $13,518,000 | $0 | - |
| Current Capital Lease Obligation | $1,343,000 | $1,188,000 | $1,047,000 | $918,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,733,000 | $4,208,000 | $4,690,000 | $5,413,000 |
| Current Accrued Expenses | $6,006,000 | $5,773,000 | $5,807,000 | $4,914,000 |
| Net PPE | $7,851,000 | $9,059,000 | $11,067,000 | $12,840,000 |
| Accumulated Depreciation | $-8,753,000 | $-7,427,000 | $-5,861,000 | $-4,418,000 |
| Gross PPE | $16,604,000 | $16,486,000 | $16,928,000 | $17,258,000 |
| Leases | $5,124,000 | $5,124,000 | $5,124,000 | $5,124,000 |
| Construction In Progress | $459,000 | $0 | $0 | $98,000 |
| Other Properties | $10,340,000 | $10,498,000 | $10,940,000 | $11,172,000 |
| Machinery Furniture Equipment | $681,000 | $864,000 | $864,000 | $864,000 |
| Properties | $0 | $0 | $0 | $0 |
| Buildings And Improvements | - | $4,587,000 | $5,125,000 | - |
Fetched: 2026-07-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-5,510,000 | $-18,414,000 | $-69,106,000 | $-77,590,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-4,992,000 | $-18,378,000 | $-68,620,000 | $-75,723,000 |
| Cash Flow From Continuing Operating Activities | $-4,992,000 | $-18,378,000 | $-68,620,000 | $-75,723,000 |
| Operating Gains Losses | $-3,561,000 | $3,000 | $3,000 | $1,000 |
| Investing Activities | ||||
| Capital Expenditure | $-518,000 | $-36,000 | $-486,000 | $-1,867,000 |
| Investing Cash Flow | $-518,000 | $-36,000 | $-486,000 | $-1,867,000 |
| Cash Flow From Continuing Investing Activities | $-518,000 | $-36,000 | $-486,000 | $-1,867,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $40,655,000 | $6,825,000 | $0 | $0 |
| Financing Cash Flow | $87,775,000 | $29,196,000 | $-6,550,000 | $-69,000 |
| Cash Flow From Continuing Financing Activities | $87,775,000 | $29,196,000 | $-6,550,000 | $-69,000 |
| Net Common Stock Issuance | $40,655,000 | $6,825,000 | $0 | $0 |
| Common Stock Issuance | $40,655,000 | $6,825,000 | $0 | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $0 | $-3,382,000 | $-6,752,000 | $-85,000 |
| Interest Paid Supplemental Data | $0 | $62,000 | $573,000 | $555,000 |
| End Cash Position | $139,338,000 | $57,073,000 | $46,291,000 | $121,947,000 |
| Beginning Cash Position | $57,073,000 | $46,291,000 | $121,947,000 | $199,606,000 |
| Changes In Cash | $82,265,000 | $10,782,000 | $-75,656,000 | $-77,659,000 |
| Proceeds From Stock Option Exercised | $47,120,000 | $25,753,000 | $202,000 | $16,000 |
| Net Issuance Payments Of Debt | $0 | $-3,382,000 | $-6,752,000 | $-85,000 |
| Net Long Term Debt Issuance | $0 | $-3,382,000 | $-6,752,000 | $-85,000 |
| Long Term Debt Payments | $0 | $-3,382,000 | $-6,752,000 | $-85,000 |
| Net PPE Purchase And Sale | $-518,000 | $-36,000 | $-486,000 | $-1,867,000 |
| Purchase Of PPE | $-518,000 | $-36,000 | $-486,000 | $-1,867,000 |
| Change In Working Capital | $25,125,000 | $31,782,000 | $-1,658,000 | $2,004,000 |
| Change In Other Working Capital | $27,877,000 | $32,780,000 | - | - |
| Change In Payables And Accrued Expense | $-827,000 | $-17,000 | $-1,888,000 | $2,070,000 |
| Change In Accrued Expense | $-979,000 | $-1,543,000 | $175,000 | $1,585,000 |
| Change In Payable | $152,000 | $1,526,000 | $-2,063,000 | $485,000 |
| Change In Account Payable | $152,000 | $1,526,000 | $-2,063,000 | $485,000 |
| Change In Prepaid Assets | $3,075,000 | $-981,000 | $688,000 | $344,000 |
| Change In Receivables | $-5,000,000 | $0 | - | - |
| Stock Based Compensation | $6,939,000 | $6,434,000 | $7,382,000 | $8,424,000 |
| Depreciation Amortization Depletion | $1,541,000 | $1,644,000 | $1,900,000 | $1,847,000 |
| Depreciation And Amortization | $1,541,000 | $1,644,000 | $1,900,000 | $1,847,000 |
| Gain Loss On Investment Securities | $-3,561,000 | - | - | - |
| Gain Loss On Sale Of PPE | $0 | $3,000 | $3,000 | $1,000 |
| Net Income From Continuing Operations | $-35,036,000 | $-58,241,000 | $-76,404,000 | $-88,222,000 |
| Change In Other Current Liabilities | - | $-1,047,000 | $-918,000 | $-801,000 |
| Change In Other Current Assets | - | $539,000 | $460,000 | $391,000 |
| Other Non Cash Items | - | - | $157,000 | $223,000 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-07-16